medigraphic.com

2011, Number 1

<< Back Next >>

Rev Fac Med UNAM 2011; 54 (1)

Diabetes mellitus type 2 treatment

Roldán VA, Ojeda CG, Roldán VEA

Language: Spanish
References: 28
Page: 28-40
PDF size: 377.47 Kb.


ABSTRACT

Currently diabetes is a sever and increasing public health problem that sets an important reduction in life expectancy and an increase in morbidity secondary to its complications. Therefore, patients suffering from diabetes mellitus (DM) types 1 or 2, require in their initial integral management exercise and a diet, along with the supplementary pharmacological management with oral and parenteral hypoglycemic agents (exenatide, insulin) for the appropriate control of glucose levels, which will diminish the chronic complications that this kind of patients usually have.


REFERENCES

  1. David M, Nathan, MD1, John B, et al. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29(8):1963-72.

  2. Rishter B, Bandeira-Echter E, Bergerhoff K, et al. Dipeptidyl peptidasa-4 (DPP-4) inhibitors for type 2 diabetes mellitas. Cocthrane Database Syst Rev. 2008;2:CD006739.

  3. Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in Consensus Statement patients with type 2 diabetes mellitas. Diabetologia. 2006;49:2564-71.

  4. Goldstein B, Feinglos M, Lunceford J, et al. Effect of inicial combination therapy with sitagliptin a dipeptidyl peptidasa- 4 inhibitor, and metformin on glucemic control in patients with type 2 diabetes. Diabetes Care. 2007;30:1979-87.

  5. Priscilla Hollander, MD. Anti-Diabetes and Anti-Obesity Medications: Effects on weight in people with diabetes. Diabetes Spectrum. 2007;20(3):159-65.

  6. Ralph A, De Fronzo MD. Pharmacologic Therapy for Type 2 Diabetes Mellitus. Annals of Internal Medicine. 1999; 131(4): 281-303.

  7. David M, Nathan, MD, John B, Buse, MD, PHD, et al. Medical management of hyperglycemia in Type 2 Diabetes: A consensus algorithm for the initiation and adjustment of therapy. Clinical Diabetes. 2009;27(1):4-16.

  8. Carracedo Martínez E. Uso de glitazonas en grupos de población gallega: Un estudio de utilización de medicamentos. Formación de Atención Primaria. 2005;3(3):68-72.

  9. Pardo Ruiz CL, Sánchez Aranda S. Papel de los nuevos hipoglucemiantes orales en el tratamiento de la Diabetes tipo 2. Formación de Atención Primaria. 2005;3(3);80-84.

  10. Hamelo Yki-Järuinen, MD. Thiazolidinediones. N Engl J Med. 2004;351:1106-18.

  11. David M, Nathan MD. Initial Management of glycemia in type 2 Diabetes Mellitus. N Engld J Med. 2002;347(17); 1342-9.

  12. Clofford J, Bailey Ph, D, MRC, Path and Robert C, Turner, MD. Metformin. New Engl J Med. 1996;334(9); 574-579.

  13. Diaz Grávalos GJ, Palmeiro Fernández G, Casado Górriz I, et all. Cumplimiento de los objetivos de control metabólico en Diabetes Mellitus en el Medio Rural de Ourense. Rev Esp Salud Pública. 2006;80(1):67-75.

  14. Ariza E, Camacho N, Londoño E, et al. Factores asociados a control Metabólico en pacientes deiabéticos tipo 2 UBA Manga de Coomeva EPS en Cartagena (Colombia). Salud Uninorte. 2005;21:28-40.

  15. Arnold Chan K, MD, ScD; Truman A, MS; Gurwitz JH, MD, et al. A cohort study of the incidence of serious acute, liver injury in diabetic patients treated with hypoglycemic agents: Arch Intern Med. 2003;163:728-34.

  16. Weiland DA, MD, and Russell D, MD. Diabetes Mellitus: linics. Family Practice. 2002;4(3):703-52.

  17. Hernández-Jimenez S, Aguilar Salinas CA, Gómez Pérez FJ. Tiazolidinedionas: Beneficios y riesgos reales. Revista de Endocrinología y Nutrición. 2002;10(2):64-76.

  18. American Diabetes Association. UK prospective diabetes study. Overview of 6 years´ therapy of type II diabetes: a progressive disease, U.K. prospective Diabetes Study Group. Diabetes. 1995;44:49-1258.

  19. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet. 1998;352:854-65.

  20. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002;359(9309):824-30.

  21. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414(6865): 782-7.

  22. Drucker DJ. Biologic actions and therapeutic potential of the proglucagón derived peptides. Nature Endocrinol Metab. 2005;1:22-31.

  23. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on Glycemic control and weight over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083-91.

  24. Heine RJ Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann Int med. 2005;143:559-569.

  25. Schmitz O, Brock B, Rungby J. Amylin agonists: a novel approach in the treatment of diabetes. Diabetes. 2004;53 (Supp, 3): s233-S238.

  26. Riddle M, Frias J, Zhang B, et al. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. Diabetes Care. 2007;30:2794-9.




2020     |     www.medigraphic.com